Long Residence Time Inhibition of EZH2 in Activated Polycomb Repressive Complex 2
Glenn S. Van Aller(GlaxoSmithKline (United Kingdom)), Ryan G. Kruger(Arysta LifeScience (France)), Michael T. McCabe(GlaxoSmithKline (United States)), Sharad K. Verma(GlaxoSmithKline (United States)), Melissa B. Pappalardi(GlaxoSmithKline (United States)), Peter J. Tummino(Intarcia Therapeutics (United States)), Elsie Diaz(Johnson & Johnson (United States)), Heidi M. Ott(GlaxoSmithKline (United Kingdom)), Caretha L. Creasy, William H. Miller(Clinical Innovations (United States)), Martín Brandt(SINTEF), Benjamin Schwartz, Dashyant Dhanak(Wilmington University)
Cited by 58
Related Papers
Genomic-sequence comparison of two unrelated isolates of the human gastric pathogen Helicobacter pylori
|Nature|1999|1.9k
EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations
|Nature|2012|1.8k
Hydrolysis of Biological Peptides by Human Angiotensin-converting Enzyme-related Carboxypeptidase
|Journal of Biological Chemistry|2002|1.4k
The promise and peril of chemical probes
|Nature Chemical Biology|2015|848